PXD034263-1

PXD034263 is an original dataset announced via ProteomeXchange.

Title	Comprehensive molecular characterization of clinical responses to PD-1 inhibition in hepatocellular carcinoma
Description	Hepatocellular carcinoma (HCC) is the sixth most common cancer and the fourth lethal cancer worldwide. We performed proteomic and metabolomic profiling of sera from 67 HCC patients who received pembrolizumab therapy and 15 healthy individuals. We then trained a machine learning model using proteomic and metabolomic measurements from a training cohort containing 26 patients with resistance to PD-1 treatment and 23 patients with response to PD-1 treatment. The model was validated using a testing cohort containing 7 patients with resistance to PD-1 treatment and 6 patients with response to PD-1 treatment, 12 of which were correctly classified. Our analysis reveals the proteomic and metabolic features of HCC patients which correlated with PD1 antibody therapy and provide serum predictive markers for selection of patients with potential response to PD1 therapy.
HostingRepository	iProX
AnnounceDate	2022-06-02
AnnouncementXML	Submission_2022-06-01_20:50:02.600.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Jian-Hang Huang
SpeciesList	scientific name: Homo sapiens; NCBI TaxID: 9606;
ModificationList	No PTMs are included in the dataset
Instrument	timsTOF Pro

Revision	Datetime	Status	ChangeLog Entry
0	2022-06-01 20:49:46	ID requested
⏵ 1	2022-06-01 20:50:02	announced

Dataset with its publication pending

submitter keyword: hepatocellular carcinoma, immunotherapy, PD-1, Proteomics, Metabolomics, machine learning, random forest

Feng Liu
contact affiliation	Fudan University Institutes of Biomedical Sciences
contact email	liuf@fudan.edu.cn
lab head
Jian-Hang Huang
contact affiliation	Fudan University Institutes of Biomedical Sciences
contact email	mzbj1996@163.com
dataset submitter

iProX dataset URI